The production of cytotoxic T cells with specificity for cancer cells is a rapidly evolving branch of cancer therapeutics. A variety of approaches aim to amplify anti-tumour cytotoxic T cell responses using purified peptides, tumour cell lysates or recombinant HLA/peptide complexes in differing antigen presenting systems. Using a two-step biotin-streptavidin antibody targeting system, recombinant HLA-class I/peptide complexes were attached to the surface of B cells via the anti-CD20 B9E9-scFvSA antibody-streptavidin fusion protein. Flow cytometry with a conformation dependant monoclonal antibody to HLA class I indicated that targeted HLA-class I/peptide complexes remain on the surface of B cells in culture for periods in excess of 72 h. PBM...
International audienceTo design an efficient procedure to expand high avidity melanoma reactive T ce...
CAR T cell therapy has shown great promise for the treatment of B cell malignancies. However, antige...
TCR with known antitumor reactivity can be genetically introduced into primary human T lymphocytes a...
A number of cell surface molecules with specificity to tumour cells have been identified and monoclo...
BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
Background: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
A number of experimental antibody mediated cancer therapies aim to redirect cytotoxic T cells (CTLs)...
A number of experimental antibody mediated cancer therapies aim to redirect cytotoxic T cells (CTLs)...
Previous attempts to treat human malignancies by adoptive transfer of tumor-specific CTLs have been ...
The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited...
To demonstrate that antibody-guided targeting of antigenic MHC class I-peptide tetramer on tumor cel...
The immunotherapy of cancer aims to activate both the humoral and cellular arms of the immune system...
The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited...
<p>(A) Frequency of antigen-specific CD8+ T cells in four T cell lines after 33 days of repeated sti...
Cyclin A1 is a promising antigen for T cell therapy being selectively expressed in high-grade ovaria...
International audienceTo design an efficient procedure to expand high avidity melanoma reactive T ce...
CAR T cell therapy has shown great promise for the treatment of B cell malignancies. However, antige...
TCR with known antitumor reactivity can be genetically introduced into primary human T lymphocytes a...
A number of cell surface molecules with specificity to tumour cells have been identified and monoclo...
BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
Background: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
A number of experimental antibody mediated cancer therapies aim to redirect cytotoxic T cells (CTLs)...
A number of experimental antibody mediated cancer therapies aim to redirect cytotoxic T cells (CTLs)...
Previous attempts to treat human malignancies by adoptive transfer of tumor-specific CTLs have been ...
The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited...
To demonstrate that antibody-guided targeting of antigenic MHC class I-peptide tetramer on tumor cel...
The immunotherapy of cancer aims to activate both the humoral and cellular arms of the immune system...
The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been exploited...
<p>(A) Frequency of antigen-specific CD8+ T cells in four T cell lines after 33 days of repeated sti...
Cyclin A1 is a promising antigen for T cell therapy being selectively expressed in high-grade ovaria...
International audienceTo design an efficient procedure to expand high avidity melanoma reactive T ce...
CAR T cell therapy has shown great promise for the treatment of B cell malignancies. However, antige...
TCR with known antitumor reactivity can be genetically introduced into primary human T lymphocytes a...